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Abstract
Podocytes, or glomerular epithelial cells, form the final layer in the
glomerular capillary wall of the kidney. Along with the glomerular basement
membrane and glomerular endothelial cells, they make up the glomerular
filtration barrier which allows the passage of water and small molecules
and, in healthy individuals, prevents the passage of albumin and other key
proteins. The podocyte is a specialised and terminally differentiated cell
with a specific cell morphology that is largely dependent on a highly
dynamic underlying cytoskeletal network and that is essential for
maintaining glomerular function and integrity in healthy kidneys. The
RhoGTPases (RhoA, Rac1 and Cdc42), which act as molecular switches
that regulate actin dynamics, are known to play a crucial role in maintaining
the cytoskeletal and molecular integrity of the podocyte foot processes in a
dynamic manner. Recently, novel protein interaction networks that regulate
the RhoGTPases in the podocyte and that are altered by disease have
been discovered. This review will discuss these networks and their potential
as novel therapeutic targets in nephrotic syndrome. It will also discuss the
evidence that they are direct targets for (a) steroids, the first-line agents for
the treatment of nephrotic syndrome, and (b) certain kinase inhibitors used
in cancer treatment, leading to nephrotoxicity.
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Introduction
The kidney is vital for the maintenance of water and electro-
lyte homeostasis and for the removal of waste metabolites 
from the blood while retaining or reabsorbing useful compo-
nents. The filtration unit of the kidney, the glomerulus is com-
posed of a bundle of capillaries, which are highly permeable to 
water yet can retain larger macromolecules while selectively 
allowing passage of solutes. This selectivity is achieved by the 
action of the glomerular filtration barrier, which comprises the 
glomerular basement membrane, glomerular endothelial cells 
and glomerular epithelial cells—or podocytes1. Terminally 
differentiated epithelial cells, podocytes are critical in preventing 
protein passage across the filtration barrier. They have branch-
ing and interdigitating processes, and filtration takes place 
through slits between these processes. A critical component 
of the filtration barrier, the slit diaphragm is an ultra-thin 
zipper-like structure that bridges the gap between interdigitat-
ing podocyte foot processes. It is a cell junction and signalling 
complex that is essential for regulating podocyte cytoskeletal 
dynamics2.
Podocytes have a remarkably elaborate and highly specialised 
morphology that critically depends on an underlying network 
of dynamic and interconnected actin and microtubule polymers 
which allow them to respond rapidly to environmental changes 
to maintain a healthy filtration barrier3,4. Damage to this unique 
cytoskeletal architecture is a hallmark of glomerular disease, 
and the importance of correct regulation of this process 
can be demonstrated by the fact that a number of human neph-
rotic syndromes (NS) are caused by genetic mutations cod-
ing for podocyte-specific proteins or proteins that seem only 
dysfunctional within the podocyte and that are associated 
with the slit diaphragm or directly link it to the podocyte actin 
cytoskeleton5. Therefore, an understanding of how the cel-
lular architecture of the podocyte is regulated in health and 
how this is disrupted in disease is essential. Recent work, 
which will be discussed in this review, has highlighted 
the crucial role of the RhoGTPases—which act as molecular 
switches regulating actin dynamics—in the unique biology 
of the podocyte and the pathogenesis of glomerular diseases. 
Excitingly, recent work has also suggested that pathways that 
regulate RhoGTPases in the podocyte are the site of action 
for steroids, the main first-line treatment for NS, thus iden-
tifying novel biological pathways that can be targeted 
therapeutically6–8.
The RhoGTPases RhoA, Rac1 and Cdc42 act as molecu-
lar switches—cycling between an active GTP-bound form 
and an inactive GDP-bound form—that are crucial regulators 
of several cellular processes, including actin and microtubule 
cytoskeletal dynamics, cell morphogenesis and cell migration9. 
The activity of these proteins is tightly regulated by a vari-
ety of guanine nucleotide exchange factors (GEFs), GTPase- 
activating proteins (GAPs) and guanine nucleotide dissociation 
inhibitors (GDIs) which act to control the ratio of the GTP- and 
GDP-bound forms9. There is substantial evidence, reviewed 
previously10, that the RhoGTPases play a crucial role in 
the regulation of podocyte biology whereby RhoA activation 
increases in actin stress fibres promoting a contractile phenotype 
whilst Rac1/Cdc42 activation increases lamellipodia/filopodia 
formation promoting cell motility11. It is known that there is 
crosstalk between the GTPases and that tight regulation of 
their activities is crucial for maintaining a healthy podocyte 
phenotype as changes to the balance of the activity of 
the small GTPases lead to hypo- or hyper-motility of podo-
cytes resulting in proteinuria7. This was recently demon-
strated in drosophila nephrocytes, which are structurally and 
functionally homologous to podocytes, where a tight balance 
of Rac1 and Cdc42 activity is essential to maintain the special-
ised architecture and function of this cell12. The RhoGTPases 
appear to have different roles in specific disease states, and 
controversy remains as to the exact role that alterations 
in their activity play in disease pathogenesis11. For exam-
ple, alterations in Rac1 activity have been shown to be both 
beneficial and detrimental to the podocyte and this may depend 
on the type of podocyte injury involved11. Inducible Rac1 acti-
vation specifically in podocytes in mice induces foot proc-
ess effacement, proteinuria and the spectrum of NS ranging 
from minimal change disease to focal segmental glomerulo-
sclerosis (FSGS)13,14. In contrast, Rac1 has also been shown to 
be important for glomerular repair as podocyte-specific knock-
out resulted in increased glomerulosclerosis via suppression 
of mammalian target of rapamycin (mTOR) activity in injured 
podocytes15.
The RhoGTPases are known to regulate or are regulated by a 
number of factors implicated in NS, such as TRPC5, TRPC6 
and suPAR16–19. Mutation analysis of patients with NS has 
recently revealed novel functional networks which regulate the 
GTPases and which are altered in disease-causing changes to the 
activity of these proteins. Braun et al. reported disease-causing 
mutations in genes encoding the nuclear pore complex proteins 
NUP107, NUP85 and NUP133 in patients with steroid-resistant 
NS and demonstrated that knockdown of any of these three pro-
teins in podocytes led to the activation of Cdc4220. Ashraf et al. 
identified mutations in six different genes (MAGI2, TNS2, 
DCL1, CDK20, ITSN1 and ITNS2) which result in partially 
treatment-sensitive NS7. These proteins interact and form com-
plexes which are involved in the regulation of the RhoGTPases, 
especially RhoA and Cdc427. MAGI2, TNS2, DCL1 and 
CDK20 form complexes that regulate RhoA whilst ITSN1 and 
2 are GEFs for Cdc42. MAGI2 also forms a complex with the 
Rap1 GEF, RapGEF2, regulating Rap1 and this complex is 
lost in the presence of the MAGI2 mutations21. Importantly, 
glucocorticoids, which are the standard treatment for NS in 
children, have been shown to act directly act on the podocyte22 
and a potential mechanism for their beneficial effect has been 
shown to be via these RhoGTPase regulatory complexes7. 
In agreement with these findings that the mode of action of ster-
oids may be via direct action on the podocyte to regulate the 
RhoGTPases, McCaffrey et al. have demonstrated that dex-
amethasone reduces the podocyte activity of Rac1, thereby 
increasing barrier function8. However, modelling MAGI2 muta-
tions in zebrafish suggest that the effectiveness of steroids 
in treating alterations in RhoGTPase activity depends on the 
specific genetic mutation involved and so unravelling the 
specific action and targets of these agents will be crucially 
important23. Maeda et al. recently delineated another protein 
pathway regulating RhoGTPase activity in the podocyte, centred 
on Ca2+/calmodulin-dependent kinase 4 (CaMK4)/synaptopodin, 
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as a potential target for treating podocytopathies such as NS24. 
Prevention of the degradation of the actin organising 
protein synaptopodin and subsequent stabilisation of the 
RhoA/Cdc42 signalling pathway by the direct action of the 
anti-proteinuric drug cyclosporin A on the podocyte have been 
reported25. It has since been shown that increased expression 
of CaMK4, which is seen in FSGS, both alters the expression 
of Rac1 and RhoA and leads to the phosphorylation of the scaf-
fold protein 14-3-3. Phosphorylation of 14-3-3 results in the pro-
teolytic cleavage of the actin organising protein synaptopodin 
because of a loss of interaction between the two proteins, caus-
ing enhanced Rac1 signalling, decreased RhoA activity and 
increased podocyte motility24,26. A CaMK4 inhibitor amelio-
rated synaptopodin degradation, alterations in RhoGTPase 
activity and changes to motility in human podocytes. Further-
more, podocyte-specific targeting of this inhibitor prevented and 
reversed podocyte injury and renal disease in both the adriamycin 
mouse model of FSGS and mice exposed to lipopolysaccharide- 
induced podocyte injury24. These results suggest that target-
ing the pathways regulating or regulated by the GTPase may be 
a novel therapeutic area for glomerular disease. Conversely, 
recent data suggested that kinase inhibitors such as deasat-
inib, used in clinical oncology, may have nephrotoxic effects by 
affecting RhoGTPase signalling in the podocyte27. Therefore, a 
clear delineation of the complex network of protein interac-
tions centred on the RhoGTPases in the podocyte and how 
they alter the specialised biology of this cell is becoming 
increasingly important.
In addition to the pathways already detailed, several other pro-
teins have been identified to be important regulators of the 
GTPases in podocytes. For example, ARHGAP24 regulates 
Rho/Rac signalling balance in podocytes and mutations in 
this protein are associated with familial FSGS28. Mutations in 
ARHGDIA (a GDI for Cdc42 and Rac1), KANK2, ARHGEF17 
and FAT1 all result in altered RhoGTPase activity and cause 
NS29–33. SLIT-ROBO pGTPase-activating protein 2a (SRGAP2a) 
suppresses podocyte motility through inactivating RhoA and 
Cdc42 and is downregulated in patients with kidney disease34. 
Trio, a GEF for Rac1, is expressed in podocytes and is signifi-
cantly upregulated in glomeruli of patients with FSGS35. Human 
FSGS-causing mutations in anillin have been shown to induce 
hyperactivation of both Rac1 and mTOR in podocytes36. Rac1 
activity is also regulated via the kindlin-2–RhoGDIα–Rac1 
signalling axis. Knockout of kindlin-2 resulted in hyperac-
tivation of Rac1 via a reduction in RhoGDIα levels and an 
increased dissociation of this protein from Rac1, leading to podo-
cyte cytoskeletal re-organisation, foot process effacement and 
massive proteinuria37. In addition, podocyte foot process 
effacement due to loss of kindlin-2 has been linked to increased 
RhoA activity and resulting changes to cortical actin struc-
tures, plasma membrane tension and focal adhesion function38. 
Rac1 activity is also regulated by the binding of RhoGDI to 
the actin regulatory protein, ezrin. The ezrin knockout mouse 
has significantly reduced Rac1 activity and is protected from 
injury-induced morphological changes39. CLIC5A, a chlo-
ride intracellular channel, stimulates podocyte Rac1 activity 
leading to the activation of both ezrin and the cytoskeleton 
regulator PAK140.
These results suggest that clearly understanding the cellu-
lar network in health and disease that both regulate and are 
regulated by RhoGTPase activity will provide new therapeutic 
targets for NS. Indeed, small-molecule inhibitors targeting the 
RhoGTPases are already being developed in the cancer field 
and several drug targets have been suggested in the NS field, 
such as TRPC5, TRPC6 and suPAR, which either are known 
modulators of or are modulated by the RhoGTPases16–19,41. 
For example, inhibition of TRPC5 which is activated down-
stream of Rac1, leading to deleterious podocyte cytoskeleton 
remodelling, has been shown to ameliorate kidney disease in 
rat models of NS19. However, as detailed above, there is already 
evidence for the involvement of multiple interactions and 
pathways in maintaining the correct balance of activity of the 
RhoGTPases and these proteins work in concert with other 
GTPases such as dynamin to regulate podocyte phenotype42, so 
unpicking this complex network will not be an easy proposition 
(Figure 1).
Figure 1. Regulation of the RhoGTPases in the podocyte.
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